Managers

Elstar Therapeutics locks in $39 mln Series A

Cambridge, Massachusetts-based Elstar Therapeutics, a provider of precision cancer immunotherapy, has raised $39 million in Series A financing. The investor was Apple Tree Partners.

Biotech company Scholar Rock lands $47 mln Series C

Scholar Rock, a biotechnology company, has secured $47 million in Series C financing. Invus led the round with participation from other investors that included Redmile Group, Polaris Partners, Timothy Springer, ARCH Venture Partners, EcoR1 Capital, The Kraft Group, Fidelity Management and Research Company and Cormorant Asset Management.

Jeff Clavier on the bifurcation in seed investing and today’s price competition for deals

Cryptocurrencies spike after report of Founders Fund's bitcoin wager

Pioneer Square Labs raises $40.8 mln venture capital fund

Pioneer Square Labs has raised a $40.8 million venture capital fund, according to a filing with the SEC.

Arsenal seeks to raise $150 mln for third fund

Arsenal has set a $150 million target for its third fund, according to an SEC filing. Arsenal is a growth equity firm focused on "the intersection of the government, large corporations and emerging technology companies."

CMAB Biopharma grabs $38 mln Series A

CMAB Biopharma Inc, a Chinese provider of process development and manufacturing services for biologic products, has raised $38 million in Series A financing. C-Bridge Capital and BioBAY led the round with participation from I-Bridge Capital and Qianhai FoF.

Centrexion rakes in $67 mln Series D in NEA-led round

Boston-based Centrexion Therapeutics Corporation, a developer of treatments for chronic pain, has closed $67 million in Series D financing. New Enterprise Associates led the round with participation from other investors that included Quan Capital, ArrowMark Partners, certain investment funds advised by Clough Capital Partners L.P., InterWest Partners, 6 Dimensions Capital and Efung Capital. In conjunction with the funding, Centrexion has appointed Dr. Sara Nayeem, a partner at NEA, and Dr. Stella Xu, a managing director at Quan Capital, to its board of directors. Leerink Partners LLC was financial adviser on the transaction.

PEAR Therapeutics scores $50 mln Series B

Boston and San Francisco-based PEAR Therapeutics, a provider of prescription digital therapeutics, has secured $50 million in Series B financing. Temasek led the round with participation from other investors that included 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, EDBI and the Bridge Builder’s Collaborative.

VC-backed LogicBio expands leadership team

Cambridge, Massachusetts-based LogicBio Therapeutics, a genome editing company, has expanded its leadership team with four new appointments: Matthias Jaffe is now chief financial officer; Tom Wilton has become chief business officer; Nelson Chau is now vice president of biology; and Kelly Blackburn is clinical and regulatory strategist. LogicBio's backers include Arix Bioscience, OrbiMed, Edmond De Rothschild Investment Partners, Pontifax, SBI and OrbiMed Israel Partners.